Evidence-based treatment of cancer-related breakthrough pain with opioids

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 11, Issue SUPPL.1, 2013, Pages

  Zeppetella, Giovambattista ^a  

^a St Clare Hospice   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FENTANYL CITRATE; MORPHINE; PLACEBO;

ANEMIA; ARTICLE; BREAKTHROUGH PAIN; CANCER PAIN; CONSTIPATION; CROSSOVER PROCEDURE; DIZZINESS; DRUG DOSAGE FORM COMPARISON; DRUG DOSE TITRATION; FATIGUE; HEADACHE; HEALTH CARE COST; HUMAN; NAUSEA; OPTIMAL DRUG DOSE; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOMNOLENCE; SYSTEMATIC REVIEW; TABLET; VERTIGO; VOMITING;

EID: 84875907252     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2013.0213     Document Type: Article

References (43)

1. Zeppetella G, Ribeiro MD. Opioids for the management of breakthrough (episodic) pain in cancer patients [review]. Cochrane Database Syst Rev 2006:CD004311.
2. Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 2012;13:e58-68.
3. Hagen NA, Fisher K, Victorino C, Farrar JT. A titration strategy is needed to manage breakthrough cancer pain effectively: observations from data pooled from three clinical trials. J Palliat Med 2007;10: 47-55.
4. Zeppetella G, Ribeiro MD. Pharmacotherapy of cancer-related episodic pain. Expert Opin Pharmacother 2003;4: 493-502.
5. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990;41: 273-281.
6. Mercadante S, Radbruch L, Caraceni A, et al. Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer 2002;94: 832-839.
7. Cherny NI, Portenoy RK. Cancer pain management. Current strategy. Cancer 1993;72(11 Suppl): 3393-3415.
8. Benedetti C, Brock C, Cleeland C, et al. NCCN Practice Guidelines for Cancer Pain. Oncology (Williston Park) 2000;14(11A): 135-150.
9. Zeppetella G. Opioids for the management of breakthrough cancer pain in adults: a systematic review undertaken as part of an EPCRC opioid guidelines project. Palliat Med 2011;25: 516-524.
10. Coluzzi PH, Schwartzberg L, Conroy JD, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 2001;91(1-2): 123-130.
11. Christie JM, Simmonds M, Patt R, et al. Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J Clin Oncol 1998;16: 3238-3245.
12. Portenoy RK, Payne R, Coluzzi P, et al. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain 1999;79(2-3): 303-312.
13. Farrar JT, Cleary J, Rauck R, et al. Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst 1998;90: 611-616.
14. Actiq [package insert]. Frazer, PA: Cephalon, Inc.; 2011.
15. Hanks G. Oral transmucosal fentanyl citrate for the management of breakthrough pain. Eur J Palliat Care 2001;8: 6-9.
16. Mercadante S, Villari P, Ferrera P, et al. Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain. Br J Cancer 2007;96: 1828-1833.
17. Darwish M, Kirby M, Robertson P Jr, et al. Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate. J Clin Pharmacol 2007;47: 343-350.
18. Fentora [package insert]. Salt Lake City, UT: Cephalon, Inc.; 2006.
19. Portenoy RK, Taylor D, Messina J, Tremmel L. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain 2006;22: 805-811.
20. Slatkin NE, Xie F, Messina J, Segal TJ. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol 2007;5: 327-334.
21. Christrup LL, Foster D, Popper LD, et al. Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, double-dummy, two-way, crossover study. Clin Ther 2008;30: 469-481.
22. Instanyl. Summary of Product Characteristics. Elverum, Norway: Nycomed Pharma AS; 2012.
23. Takeda Web site. Nycomed's Instanyl® is first intranasal fentanyl approved in Europe for managing breakthrough pain in cancer [news release]. July 24, 2009. Available at: http://www.nycomed. com/media/news-releases/2009/ nycomeds%20instanyl% 20is%20first%20intranasal%20fentanyl%20approved%20in%20 europe/. Accessed August 7, 2012.
24. Kress HG, Oronska A, Kaczmarek Z, et al. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 μg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period. Clin Ther 2009;31: 1177-1191.
25. Mercadante S, Radbruch L, Davies A, et al. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial. Curr Med Res Opin 2009;25: 2805-2815.
26. Vissers D, Stam W, Nolte T, et al. Efficacy of intranasal fentanyl spray versus other opioids for breakthrough pain in cancer. Curr Med Res Opin 2010;26: 1037-1045.
27. Vissers DC, Lenre M, Tolley K, et al. An economic evaluation of short-acting opioids for treatment of breakthrough pain in patients with cancer. Value Health 2011;14: 274-281.
28. Lennernäs B, Frank-Lissbrant I, Lennernäs H, et al. Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain: results from a randomized phase II study. Palliat Med 2010;24: 286-293.
29. Rauck RL, Tark M, Reyes E, et al. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin 2009;25: 2877-2885.
30. Fallon M, Reale C, Davies A, et al. Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study. J Support Oncol 2011;9: 224-231.
31. Portenoy RK, Burton AW, Gabrail N, Taylor D. A multicenter, placebo-controlled, double-blind, multiple-crossover study of fentanyl pectin nasal spray (FPNS) in the treatment of breakthrough cancer pain. Pain 2010;151: 617-624.
32. Rauck R, North J, Gever LN, et al. Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study. Ann Oncol 2010;21: 1308-1314.
33. Mercadante S. Pharmacotherapy for breakthrough cancer pain. Drugs 2012;72: 181-190.
34. Howell J. Pharmacotherapy for breakthrough cancer pain. Drugs 2012;72: 1009.
35. Abstral [package insert]. Lincoln, NE: Novartis Consumer Health, Inc.; 2011.
36. Onsolis [package insert]. Somerset, NJ: MEDA Pharmaceuticals, Inc.; 2011.
37. Lazanda [package insert]. Bedminster, NJ: Archimedes Pharma US Inc.; 2011.
38. Payne R, Coluzzi P, Hart L, et al. Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain. J Pain Symptom Manage 2001;22: 575-583.
39. Hanks GW, Nugent M, Higgs CMB, Busch MA. Oral transmucosal fentanyl citrate in the management of breakthrough pain in cancer: an open, multicentre, dose-titration and long-term use study. Palliat Med 2004;18: 698-704.
40. Weinstein SM, Messina J, Xie F. Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: a long-term, open-label safety study. Cancer 2009;115: 2571-2579.
41. Nalamachu S, Hassman D, Wallace MS, et al. Long-term effectiveness and tolerability of sublingual fentanyl orally disintegrating tablet for the treatment of breakthrough cancer pain. Curr Med Res Opin 2011;27: 519-530.
42. Portenoy RK, Raffaeli W, Torres LM, et al. Long-term safety, tolerability, and consistency of effect of fentanyl pectin nasal spray for breakthrough cancer pain in opioid-tolerant patients. J Opioid Manag 2010;6: 319-328.
43. Smith H. A comprehensive review of rapid-onset opioids for breakthrough pain. CNS Drugs 2012;26: 509-535.